Needham Reiterates Buy on Paragon 28, Maintains $17 Price Target
$FNA
Medical/Dental Instruments
Health Care
Needham analyst Mike Matson reiterates Paragon 28 (NYSE:FNA) with a Buy and maintains $17 price target.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2023 | Outperform | William Blair | |
| 4/11/2023 | $23.00 | Overweight | Stephens |
| 12/14/2022 | $32.00 | Buy | B. Riley Securities |
| 3/9/2022 | $30.00 → $25.00 | Buy | B of A Securities |
| 3/9/2022 | $25.00 → $23.00 | Buy | Canaccord Genuity |
| 2/9/2022 | $31.00 → $25.00 | Buy | Needham |
| 11/9/2021 | $30.00 | Market Outperform | JMP Securities |
| 11/9/2021 | $28.00 | Buy | Canaccord Genuity |
JMP Securities analyst David Turkaly maintains Paragon 28 (NYSE:FNA) with a Market Outperform and lowers the price target from $23 to $20.
During the last three months, 7 analysts shared their evaluations of Paragon 28 (NYSE:FNA), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $16.57, along with a high estimate of $18.00 and a low estimate of $14.00. This current average has decre
Piper Sandler analyst Matt O'Brien reiterates Paragon 28 (NYSE:FNA) with a Overweight and lowers the price target from $18 to $15.
OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r
Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021. "I am very pleased to welcome Kris Johnson to our board of directors, as she brings a breadth of med-tech industry leadership and commercial strategy expertise. Kris' expertise in growing medical device businesses will be essential as we expand our commercial infrastructure to be the market leader in the foot and ankle industry," said Albert DaCosta, Founder and CEO of Paragon 28. "We are also excited to welcome Krissy Wright to
SC 13G - Paragon 28, Inc. (0001531978) (Subject)
SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)
SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)
William Blair initiated coverage of Paragon 28 with a rating of Outperform
Stephens initiated coverage of Paragon 28 with a rating of Overweight and set a new price target of $23.00
B. Riley Securities resumed coverage of Paragon 28 with a rating of Buy and set a new price target of $32.00
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Chadi Chahine has been appointed Chief Financial Officer and Executive Vice-President of Supply Chain Operations, effective August 5, 2024. The Company also reported financial results for the quarter ended June 30, 2024, and narrowed its 2024 net revenue guidance. Recent Business Updates Strengthened executive leadership team with appointment of Chadi Chahine as CFO & EVP Supply Chain Operations, effective August 5, 2024 Recorded global revenue of $61.0 million in the second quarter, representing 19.6% and 19.7% r
Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Chadi Chahine, CFO, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company's website at ir.paragon28.com. About Paragon 28, Inc. Based in Englewood, Colo., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedi
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
144 - Paragon 28, Inc. (0001531978) (Subject)
8-K - Paragon 28, Inc. (0001531978) (Filer)
10-Q - Paragon 28, Inc. (0001531978) (Filer)